Firefly Luciferase mRNA

Firefly Luciferase mRNA (0.02-4.60 μg/mL; 5 h treatment incubation, 48 h post-treatment measurement) transfection of Jurkat cells results in limited, non-linear luciferase expression and significant cytotoxicity, with cell viability dropping to 40-50% at high mRNA concentrations^[1].
Firefly Luciferase mRNA (0.02-4.60 μg/mL; 5 h treatment incubation, 48 h post-treatment measurement) transfection of L-929 cells produces limited luciferase expression that peaks at 3 μg/mL mRNA before declining, with no associated cytotoxicity across tested concentrations^[1].
Firefly Luciferase mRNA (0.02-4.60 μg/mL; 5 h treatment incubation, 48 h post-treatment measurement) transfection of HEK 293 T cells produces a strong, linear dose-dependent increase in luciferase expression across 0.02 to 4.60 μg/mL mRNA with no cytotoxicity, but exhibits high intra-group variability^[1].
Firefly Luciferase mRNA (50 ng; 24 h) delivered via 4A3-SCC-PH LNPs to nontransfected MDA-MB-231 cells successfully produces functional firefly luciferase, enabling sensitive detection of endogenous H₂S via H-Luc with a 68-fold increase in bioluminescence intensity relative to untreated cells^[2].
Firefly Luciferase mRNA (50 ng; 24 h) delivered via 4A3-SCC-PH LNPs to nontransfected IGROV-1 cells successfully produces functional firefly luciferase, enabling sensitive detection of endogenous H₂S via H-Luc^[2].
Firefly Luciferase mRNA (50 ng; 24 h) delivered via 4A3-SCC-PH LNPs to oleic acid-induced NAFLD AML-12 cells successfully produces functional firefly luciferase, enabling detection of elevated endogenous H₂S with a 3.7-fold higher bioluminescence intensity relative to normal AML-12 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.